A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 3, 2009, Pages 335-337

  Harris, Marianne ^a   Coîté, Hélène ^b   Ochoa, Claudia ^c   Allavena, Clotilde ^d   Negredo, Eugenia ^e   Thorne, Anona ^a   Cahn, Pedro ^c   Zala, Carlos ^c   Raffi, Francois ^d   Clotet, Bonaventura ^e   Singer, Joel ^a   Montaner, Julio ^b  

^a Canadian HIV Trials Network   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d HÔTEL DIEU   (France)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LETTER; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSAMINITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; DRUG COMBINATION; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; VIRAL LOAD; ZIDOVUDINE;

EID: 63149158747     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181938fc9     Document Type: Letter

References (24)

1. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS. 1998;12:1735-1744.
2. Cote HCF, Brumme ZL, Alexander CS, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
3. Cote HC, Yip B, Asselin JJ, et al. Mitochon-drial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HlV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis. 2003;187:1972-1976.
4. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviral-na'ive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55: 800-804.
5. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006;66:1275-1299.
6. Van der Valk M, Kastelein JJP Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15: 2407-2414.
7. Clotet B, van der Valk M, Negredo E, et al. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr. 2003;34: S79-S84.
8. Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis. 2005;192:545-546.
9. Degen O, Kurowsky M, van Lunzen J, et al. Steady state pharmacokinetics (PK) of lopina-vir (LPV) in combination with nevirapine (NVP) or efavirenz (EFV) [TuBe4573]. Presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
10. Negredo E, Molto J, Burger D, et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA Study). J Acquir Immune Defic Syndr. 2005;38:47-52.
11. Murphy R, Zhang Z, Hafner R, et al. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoa-trophy: 24-week results of a prospective randomized clinical trial, AACTG 5110 [45LB]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
12. Benson CA, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
13. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS. 1998;12:1735-1744.
14. Cote HCF, Brumme ZL, Alexander CS, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
15. Cote HC, Yip B, Asselin JJ, et al. Mitochon-drial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HlV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis. 2003;187:1972-1976.
16. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviral-na'ive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55: 800-804.
17. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006;66:1275-1299.
18. Van der Valk M, Kastelein JJP Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15: 2407-2414.
19. Clotet B, van der Valk M, Negredo E, et al. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr. 2003;34: S79-S84.
20. Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis. 2005;192:545-546.
21. Degen O, Kurowsky M, van Lunzen J, et al. Steady state pharmacokinetics (PK) of lopina-vir (LPV) in combination with nevirapine (NVP) or efavirenz (EFV) [TuBe4573]. Presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
22. Negredo E, Molto J, Burger D, et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA Study). J Acquir Immune Defic Syndr. 2005;38:47-52.
23. Murphy R, Zhang Z, Hafner R, et al. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoa-trophy: 24-week results of a prospective randomized clinical trial, AACTG 5110 [45LB]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
24. Benson CA, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.